Abstract:Summary Background Relapse remains high in patients with myelodysplastic syndrome-refractory anaemia with excess blasts (RAEB) or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation (HSCT). We aimed to investigate whether granulocyte-colony stimulating factor (G-CSF) and decitabine plus busulfan–cyclophosphamide conditioning reduced relapse compared with busulfan–cyclophosphamide in this population. Methods We did an open-label, randomised, phase 3 trial at six hospitals in China. Eligible patients (aged 14–65 years) had myelodysplastic syndrome-RAEB or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome, and an Eastern Cooperative Oncology Group performance status of 0–2 and HSCT comorbidity index of 0–2. Patients were randomly assigned (1:1) to receive G-CSF, decitabine, and busulfan–cyclophosphamide conditioning or busulfan–cyclophosphamide conditioning. Randomisation was done with permuted blocks (block size four) with no stratification and was implemented through an interactive web-based response system, which was independent of study site staff and investigators. G-CSF, decitabine, and busulfan–cyclophosphamide conditioning comprised G-CSF 5 μg/kg daily subcutaneously (days –17 to –10), decitabine 20 mg/m 2 daily intravenously (days –14 to –10), busulfan 3·2 mg/kg daily intravenously (days –7 to –4), and cyclophosphamide 60 mg/kg daily intravenously (days –3 and –2). Busulfan–cyclophosphamide conditioning comprised the same dose and duration of busulfan and cyclophosphamide. The primary endpoint was 2 year cumulative incidence of relapse. All efficacy and safety endpoints were assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02744742; the trial is complete. Findings Between April 18, 2016, and Sept 30, 2019, 297 patients were screened for eligibility, 202 of whom were randomly assigned to G-CSF, decitabine, and busulfan–cyclophosphamide (n=101) or busulfan–cyclophosphamide (n=101) conditioning. 123 (61%) participants were male and 79 (31%) were female. Median follow-up was 32·4 months (IQR 10·0–43·0). The 2-year cumulative incidence of relapse was 10·9% (95% CI 5·8–17·9) in the G-CSF, decitabine, and busulfan–cyclophosphamide group and 24·8% (16·8–33·5) in the busulfan–cyclophosphamide group (hazard ratio 0·39 [95% CI 0·19–0·79]; p=0·011). Within 100 days after transplantation, the most common grade 3–4 adverse events in the G-CSF, decitabine, and busulfan–cyclophosphamide group and the busulfan–cyclophosphamide group were infections (34 [34%] and 32 [32%]), acute graft-versus-host disease (30 [30%] and 30 [30%]), and gastrointestinal toxicity (28 [28%] and 29 [29%]). 11 (11%) patients in the G-CSF, decitabine, and busulfan–cyclophosphamide group and 13 (13%) in the busulfan–cyclophosphamide group died of adverse events. There were no treatment related deaths. Interpretation Our results suggest that G-CSF, decitabine, and busulfan–cyclophosphamide conditioning is a better choice than busulfan–cyclophosphamide conditioning for patients with myelodysplastic syndrome-RAEB or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic HSCT. This conditioning could be a suitable therapuetic option for this patient population. Funding None. Translation For the Chinese translation of the abstract see Supplementary Materials section.

The Impact of Prophylactic Post-Chemotherapy G-CSF on the Relapse Rates in Patients with Acute Myeloid Leukemia: A Meta-Analysis

Effectiveness and safety of primary prophylaxis with G-CSF after induction therapy for acute myeloid leukemia: a systematic review and meta-analysis of the clinical practice guidelines for the use of G-CSF 2022 from the Japan society of clinical oncology

Modified Cladribine, Cytarabine, and G-CSF As a Salvage Regimen in Patients with Relapsed/refractory Acute Myeloid Leukemia: a Bridge to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.

Application of G-CSF in high-leukocyte acute myeloid leukemia is a poor prognostic factor

Impact of Rhg-Csf on Clinical Efficacy and Immune Cell Subsets after Initial Induction Chemotherapy in AML

Associations of Granulocyte Colony-Stimulating Factor with Toxicities and Efficacy of Chimeric Antigen Receptor T-cell Therapy in Relapsed or Refractory Multiple Myeloma

Application of Recombinant Human Granulocyte Colony Stimulating Factor in Children with Acute Myeloid Leukemia.

Effectiveness and safety of granulocyte colony-stimulating factor priming regimen for acute myeloid leukemia: A systematic review and meta-analysis of the Clinical Practice Guideline for the use of G-CSF 2022 from the Japan Society of Clinical Oncology

Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy

A Meta-Analysis of CAG (cytarabine, Aclarubicin, G-CSF) Regimen for the Treatment of 1029 Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

A Meta-Analysis of CAG (cytarabine, Aclarubicin, G-CSF) Regimen for the Treatment of 1045 Patients with Leukemia in China and Japan,

Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer

Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial

The effect of recombinant GM-CSF and G-CSF on the bone marrow cells of children with acute lymphoblastic leukemia.

A Single-Center,randomized Controlled Trial of PEG-rh G-CSF and Common Rh G-CSF to Promote Neutrophil Recovery after Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia

Prevention of Relapse Using Granulocyte CSF-primed PBPCs Following HLA-mismatched/haploidentical, T-cell-replete Hematopoietic SCT in Patients with Advanced-Stage Acute Leukemia: a Retrospective Risk-Factor Analysis

Efficacy and tolerability of granulocyte colony-stimulating factors in cancer patients after chemotherapy: A systematic review and Bayesian network meta-analysis

Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022

Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022